Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 10 | 13 | +0,22 % | ||
| COMPASS PATHWAYS | 6 | 11 | +0,61 % | ||
| REGENERON PHARMACEUTICALS | 5 | 22 | -0,80 % | ||
| MODERNA | 4 | 16 | +0,49 % | ||
| ANAPTYSBIO | 3 | 2 | -0,72 % | ||
| BIOGEN | 2 | 54 | -0,43 % | ||
| INTELLIA THERAPEUTICS | 2 | 5 | +0,17 % | ||
| TRAVERE THERAPEUTICS | 1 | 11 | -0,58 % | ||
| HALOZYME THERAPEUTICS | 1 | 6 | -0,32 % | ||
| VERTEX PHARMACEUTICALS | 1 | 5 | +0,34 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:34 | Omeros: Wie eine Fair-Value-Analyse den 74-%-Ausbruch der Biotech-Aktie vorhersagte | 2 | Investing.com Deutsch | ||
| 12:30 | EILMELDUNG bei Biontech: Könnte die Aktie jetzt komplett einbrechen? - Was Sie vor Montag noch wissen müssen | Hebelschein-Spekulant | |||
| 10:21 | Curevac verklagt US-Konzern Moderna wegen Patentverletzungen | 40 | manager-magazin.de | ||
| 08:13 | Psychiatrie-Revolution? Emyria Limited baut globale Service-Schiene für Sponsoren wie Eli Lilly und Compass Pathways aus | Small- & Micro Cap Investment | |||
| Fr | CureVac sues Moderna for patent infringement over COVID-19 vaccines | 16 | Reuters | ||
| Fr | CureVac sues Moderna over mRNA vaccine patents | 10 | Investing.com | ||
| Fr | CureVac verklagt Moderna wegen Patentverletzung bei mRNA-Impfstoffen | 23 | Investing.com Deutsch | ||
| Fr | Biogen: BofA erhöht Kursziel wegen stabilem Kerngeschäft auf 200 US-Dollar | 3 | Investing.com Deutsch | ||
| Fr | BofA raises Biogen stock price target to $200 on base business | 3 | Investing.com | ||
| Fr | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Fr | Intellia to report Phase 3 CRISPR gene editing trial results Monday | 28 | Investing.com | ||
| Fr | Intellia Therapeutics, Inc.: Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 | 25 | GlobeNewswire (USA) | ||
| Fr | Gericht in Delaware weist Klage von Tesaro gegen AnaptysBio ab | 1 | Investing.com Deutsch | ||
| Fr | Delaware court dismisses Tesaro breach claim against AnaptysBio | 1 | Investing.com | ||
| Fr | AnaptysBio, Inc.: Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim | 151 | GlobeNewswire (Europe) | Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against... ► Artikel lesen | |
| Fr | NewAmsterdam Pharma Co N.V. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Eton Pharmaceuticals (ETON) Appoints Judith M. Matthews as New CFO | 1 | Insider Monkey | ||
| Fr | Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment | 5 | Insider Monkey | ||
| Fr | HALOZYME THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Sanofi: Sanofi successfully prices 2.3 billion of bond issue | 609 | GlobeNewswire (Europe) | Sanofi successfully prices 2.3 billion of bond issue
Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches:
€1,000... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.